FYARRO is the first and only mTOR inhibitor using nab technology engineered to deliver high levels of drug to tumors1,2

FYARRO is the first and only mTOR inhibitor using nab technology engineered to deliver high levels of drug to tumors1,2

Significantly higher tumor accumulation vs oral mTOR
inhibitors in vivo1
*

From a study of UMUC3 human bladder cancer xenografts in athymic nude mice receiving equivalent weekly doses (15 mg/kg/week) of IV FYARRO (7.5 mg/kg, 2x/week) or oral sirolimus or everolimus (3 mg/kg, 5x/week).1
Adapted from Hou et al. Aadi Bioscience, Inc. 2019.

Nonclinical studies demonstrated significant pharmacodynamic improvement over oral mTOR inhibitors, including1,3*:

  • Enhanced bioavailability
  • Higher tumor drug concentrations
  • Increased mTOR target suppression
  • Stronger antitumor activity

*

Nonclinical data may not correlate with clinical outcomes.

AUC=area under the curve; IV=intravenous; mTOR=mechanistic target of rapamycin; UMUC3=University of Michigan-Urothelial Carcinoma-3.

References: 1. Hou S, Schmid AN, Desai N. ABI-009 (nab-sirolimus) improves tumor accumulation and antitumor activity over oral mTOR inhibitors. Poster presented at: AACR Annual Meeting; Atlanta, GA; March 29-April 3, 2019. 2. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, et al. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013;19(19):5474-5484. doi:10.1158/1078-0432.CCR-12-3110 3. Wagner AJ, Ravi V, Riedel RF, et al. Final analysis from AMPECT, an open-label phase 2 registration trial of nab-SIROLIMUS for patients with advanced malignant perivascular epithelioid cell tumors (PEComa). Abstract presented at: CTOS Virtual Annual Meeting; November 12, 2021.